Entrada Therapeutics (TRDA) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Entrada Therapeutics

NasdaqGM•Healthcare•Biotechnology

$7.13-0.04(-0.01%)Market closed

Market Cap

$285.00M

P/S

60.8x

P/B

1.2x

Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle, therapeutic candidates are based on a novel therapeutic; a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases. Its preclinical product includes ENTR-601-44; ENTR-601-45; and VX-670. The company was formerly known as CycloPorters, Inc., and changed its name to Entrada Therapeutics, Inc., in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

How this company scores

WeakMetricSide Score: 28/100

Strongest: Balance Sheet & Red Flags (15/25); weakest: Growth (3/25).

Profitability4/25

Growth3/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality6/25

Strengths

Interest easily coveredNet cash position

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 15.0x5y range 4.7x – 19.6x

Currently above its 5-quarter median.

P/S · 60.8x5y range 2.0x – 85.8x

Currently above its 14-quarter median.

P/B · 1.2x5y range 0.4x – 2.4x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 8 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $285.00M

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $4.69M
Q. Revenue: $898,000
TTM EBITDA: $-172.76M
TTM Op. Income: $-176.53M
Q. Op. Income: $-44.96M
TTM Net Income: $-165.78M
Q. Net Income: $-42.76M
EPS: $-1.01
Shares Out.: $42.22M

$4.69M in TTM revenue declined 94.1% YoY, reaching $898,000 last quarter. TTM EBITDA of $-172.76M and TTM operating income of $-176.53M show growth is flowing through to the bottom line. However, net income is negative at $165.78M — growth is not yet reaching the bottom line. Across the last 8 quarters, TTM revenue has fallen for 7 consecutive quarters — a weakening trend.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin: -4913.4%
Op. Margin: -5007.0%
Net Margin: -4762.0%

Op. margin of -5007.0% is down 2604.5% YoY — costs are rising relative to revenue. Net margin at -4762.0% Across the last 8 quarters, operating margin has fallen for 6 consecutive quarters — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 60.8x
P/B Ratio: 1.2x

P/S of 60.8x and P/B of 1.2x. P/S is high, meaning growth expectations are priced in. Over the past year, P/E is up 0% — a weakening trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $298.88M
Cash: $99.28M
Long-Term Debt: N/A
Book Value: $233.41M
D/E Ratio: N/A
Debt/EBITDA: N/A

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-32.46M
TTM Free Cash Flow: $-134.35M
FCF Margin: -2867.1%
FCF / Net Income: 0.8

TTM FCF of $-134.35M on $-32.46M in operating cash flow. The FCF / Net Income ratio of 0.8x means free cash flow covers net income — earnings are backed by cash. Across the last 8 quarters, free cash flow has fallen for 2 consecutive quarters — a weakening trend.